Several possible studies
Story checked
New study explores psychedelic therapy for co-occurring cocaine addiction and depression (opens in a new tab)
news-medical.net · 2026-10-22
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
New study explores psychedelic therapy for co-occurring cocaine addiction and depression
news-medical.net · 2026-10-22
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedUTHealth Houston researchers have been awarded a five-year, $3.4 million grant to study whether psilocybin-assisted therapy is a viable treatment option for people with co-occurring cocaine use disorder and major depressive disorder.View evidenceHide evidence
As statedfive-year, $3.4 million grant
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 6Not checkedParticipants will also receive multiple acceptance and commitment therapy sessions before and after receiving psilocybin, and the team hopes the combination will reduce depressive symptoms and increase abstinence from cocaine.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 6Not checkedAbout 50 adults diagnosed with both cocaine use disorder and major depressive disorder will be enrolled in a 12-week study and receive up to two doses of psilocybin at a UTHealth Houston clinic.View evidenceHide evidence
As statedabout 50 adults; 12-week study; up to two doses
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 6Not checkedResearchers will also evaluate brain scans taken throughout the study to observe changes in response to the drug.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 6Not checkedThe article says cocaine use disorder affects about 1.4 million people in the United States, and lifetime prevalence estimates of depression in this population are as high as 40%.View evidenceHide evidence
As statedabout 1.4 million; as high as 40%
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 6 of 6Not checkedThe article says there are no FDA-approved interventions for cocaine addiction, unlike major depressive disorder.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.
Cureus · 2026 · PubMed
Psilocybin with Acceptance and Commitment Therapy (ACT) for the Treatment of Social Anxiety Disorder (SAD)
Crossref
Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.
2026 · Europe PMC
Toward an Optimal Framework for Psilocybin Regulation: A Comparison of State Regulatory Approaches Across Key Dimensions.
The Journal of Legal Medicine · 2026 · PubMed
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
2021 · Crossref